Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal intranasal. Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variantsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition adenoviral vector Adenovirus adenovirus type 5 vector vaccine Anti-RBD IgG booster COVID-19 COVID-19 vaccine D614G demonstrated dose effective Efficacy IgA immunization Inactivated vaccine Inactivated Vaccines Inhaled lack mucosal Neutralization assay Neutralizing neutralizing antibody omicron Omicron variant BA.5 pandemic plasma Protective RBD SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 vaccines SARS-CoV-2 variant subunit titre Vaccination strategies vaccination strategies. Vaccination strategy Vaccine variant virus widespread [DOI] 10.1080/22221751.2022.2132881 PMC 바로가기
The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockadeArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Activation acute respiratory syndrome alteration analysed anti-SARS-CoV-2 anti-SARS-CoV-2 IgG anti-TNF-α appear Autoimmune Autoimmune diseases blockade bystander Cell changes in chronic inflammatory disease Cohort comparable Control coronavirus COVID-19 Decline drugs Effect Efficacy ELISA flow cytometry groups healthy humoral immune response IgG immune cell populations immune response immunoblot investigated less Live virus Necrosis Neutralization assay neutralize neutralizing antibody neutralizing capacity Older omicron Patient patients plasma Plasma cell recipient reduced response SARS-CoV-2 second vaccination significantly T cell subset titre TNF-α TNFα tumor necrosis factor inhibitors tumor necrosis factor-α vaccination vaccination. Vaccine variants of concern virus VoC was increased while [DOI] 10.1002/jmv.28063 PMC 바로가기
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants variants. [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
Persistence of SARS-CoV-2 neutralizing antibodies longer than 13 months in naturally infected, captive white-tailed deer ( Odocoileus virginianus), TexasArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] collected eight Frame increases in neutralizing antibody Odocoileus Odocoileus virginianus persistence plaque reduction neutralization PRNT SARS-CoV-2 SARS-CoV-2 neutralizing antibody Seroconversion seronegative serum sample spillover titre waned white-tailed deer. [DOI] 10.1080/22221751.2022.2112913 PMC 바로가기
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRVSARS-CoV-2 단백질 소단위 백신 ZF2001 및 mRNA 백신 RRV의 타고난 면역 특징의 전사체 분석Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 유전자 메커니즘, 진단, [키워드] Activation Analysis Anti-viral antibody approach binding CD74 Cell comparable COVID-19 cytokine Cytokines early response elicited expression level expression of gene framework Gene Expression Genes immune response immune responses immunization innate immune innate immune response Innate immunity involved mapped MHC class mRNA mRNA vaccine neutralization Neutralization antibody Pattern recognition pattern recognition receptor Pattern recognition receptors post vaccination Protein subunit protein subunit vaccine PRRs RNA degradation robust SARS-CoV-2 SARS-CoV-2 protein subunit Subunit vaccine Tap1 titre titres Transcription transcriptional Transcriptome transcriptome sequencing Transcriptome sequencing. transcriptomic transduction Vaccine ZF2001 [DOI] 10.1080/22221751.2022.2059404 PMC 바로가기 [Article Type] Article
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamstersArticle Published on 2022-11-042022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Antigen B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta block Community COVID-19 vaccine current Delta delta variant detectable Efficacy eliminating expressed Fever Gamma hamster immunization Lineage Lung pathology maintain Neutralizing antibody response omicron P.1 pandemic predominant Prevent PROTECT SARS-CoV-2 strains SARS-CoV-2 variant sequence Spread titre Transmission Vaccine variants variants of concern vectored vaccine virus VoC VOCs [DOI] 10.1038/s41467-022-34439-7 PMC 바로가기